## **Lockington, Elliott (SPAC/PSPC)**

From: Parmar, Dovejot (SPAC/PSPC)
Sent: March 22, 2020 1:07 PM

**To:** Mullan-Boudreau, Caitlin (SPAC/PSPC)

**Subject:** FW: Rapid Coronavirus Test now available: 90.9% sensitivity and 91% negative

predictive value

**FYI** 

## **Dove Parmar**

Special Assistant - Ontario | Adjoint spécial - Ontario
Office of the Honourable Anita Anand | Bureau de l'honorable Anita Anand
Public Services and Procurement Canada | Services publics et Approvisionnement Canada
dovejot.parmar@canada.ca

From: Kurusamy, Gowthaman (HC/SC)

Sent: March-21-20 10:32 PM

To: Parmar, Dovejot (SPAC/PSPC) <dovejot.parmar@canada.ca>

Subject: Fwd: Rapid Coronavirus Test now available: 90.9% sensitivity and 91% negative predictive value

Hey Dove,

If you flip this to your officials would they reach out?

## Gowthaman Kurusamy

Regional Advisor, Ontario & Western and Northern (Interim) | Conseiller régional, Ontario & Ouest et Nord (par intérim)

Office of the Minister of Health | Cabinet de la ministre de la Santé

Gowthaman.Kurusamy@canada.ca
Office/Bureau:(613) 957-0200

M: (613) 868-6988

Sent from my iPhone

Begin forwarded message:

From: "Hajdu, Patty - Assistant 2" < Patty. Hajdu. A2@parl.gc.ca>

Date: March 21, 2020 at 10:28:59 PM EDT

To: "Kurusamy, Gowthaman (HC/SC)" < gowthaman.kurusamy@canada.ca>

Subject: Fw: Rapid Coronavirus Test now available: 90.9% sensitivity and 91% negative

predictive value

From: Bianca d'Errico <bde@hboconsult.com>

Sent: March 21, 2020 10:08:32 PM

To: Hajdu, Patty - M.P.

**Cc:** Hinnerk Boriss

Subject: Rapid Coronavirus Test now available: 90.9% sensitivity and 91% negative predictive value

Dear Ms. Hajdu,

My name is Bianca d'Errico and my colleague Dr. Hinnerk Boriss (cc'd) and I have access to over 10 million Rapid Corona Virus tests ready to be deployed in Canada's Healthcare System. We are reaching out to government officials in order to expedite the procurement process as COVID-19 cases continue to rise rapidly in Canada.

The 15-minute coronavirus test is now available to ease the strain caused by the COVID-19 pandemic on healthcare systems across Europe, this comes as world leaders look for solutions to combat the disease. These particular rapid test kits have helped China to maneuver quickly through the COVID19 crisis and will be deployed in the US on a nation-wide level.

Using easy to collect samples, the tests detect the IgM and IgG antibodies response to the coronavirus, to identify if patients have contracted COVID-19 within minutes of testing.



The technology, which has already been used in China, will improve the detection rate of patients carrying COVID-19, allowing doctors to test suspected carriers as soon as 2 days after suspected exposure.

The antibody test, which was approved for sale in European markets last week, promises to ease pressure on labs by providing rapid point-of-care diagnostics.

This will assist healthcare professionals to clinically assess patients with and without symptoms, so they can provide vital care to those most in need even quicker.

Total coronavirus cases are set to surpass 287,000 worldwide today, and having been granted CE Mark certification, the tests can be made available immediately, with manufacturing being increased to meet demand over the coming weeks.

Today, the US administration placed an order of 300 million test kits from our consortium of Chinese manufacturers. This allows the US to test the entire population and guide decisions on quarantines, economic aid and focused healthcare support.

Last week, the British Prime Minister, Boris Johnson, committed to procuring several hundred thousand COVID-19 rapid tests.

This week, Germany's National Association of Statutory Health Insurance Physicians said that the weekly testing load hast reached 200.000 test per week and is approaching capacity limits. COVID19 rapid tests with a sensitivity of 90.9% and a negative predictive value of 91.7% are well suited to complement the outstanding work at the leading labs at the Charité and the Robert Koch Institute.

## Use case examples:

- 1. To relieve pressure on centralized testing units that require laboratory machinery and expert staff which are already overloaded and overwhelmed.
- 2. To assure that system relevant workers (physicians, nurses, cashiers, police, public transport etc) remain COVID19 negative so that they can keep serving the public.
- 3. To rapidly identify transmission events from contact lists of known positive patients.
- 4. To protect police and border patrols as well as their families by regular testing and thus early detection of infections.
- 5. To improve policy decisions on quarantines, healthcare spending and economic aid by nationwide testing.
- 6. To rapidly respond to infections in refugee camps.

HBO consult GmbH is partner of a Chinese consortium of SARS-CoV-2 GICA test kit manufacturers with a high quantity of reserved production capacity. As global demand is increasing daily it is mandatory to act fast to assure the required testing capacity.

In these tough times, we wish you and your family good health, solidarity, and the energy that it takes to master COVID19's challenges. Let's do everything we can to handle the pandemic and alleviate human tragedies.

Please don't hesitate to let us know if you have any questions.

Dr. Hinnerk Boriss

HBO consult GmbH

Leipzig, Germany

hbo@hboconsult.com

+49 173 3838 318

Bianca d'Errico

HBO consult GmbH

Vancouver, Canada

bde@hboconsult.com

+1 (604) 345 2002

HBO consult GmbH - Ulrichstr. 6 - 04155 Leipzig - Germany - CEO: Dr. H. Boriss - HRB (Hamburg) 148261